Zenas BioPharma

Historical price data

Zenas BioPharma is a clinical-stage biopharma company focused on developing and commercializing therapies for autoimmune diseases. Its strategy centers on acquiring and advancing late-stage assets with validated mechanisms, such as the bifunctional antibody obexelimab and the BTK inhibitor orelabrutinib, to address large market opportunities. The company is led by an experienced team with a proven track record in drug development and commercialization, operating with a patient-centric mission and a sense of urgency.

Asset-centric development strategy focused on in-licensing and advancing clinical-stage immunology programs with validated mechanisms and franchise potential across multiple indications.